Citius Pharmaceuticals, Inc. (CTXR)
| Market Cap | 292.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.37M |
| Shares Out | 55.58M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 1.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $2.17 |
| Previous Close | $2.18 |
| Change ($) | -0.01 |
| Change (%) | -0.46% |
| Day's Open | 2.18 |
| Day's Range | 2.10 - 2.25 |
| Day's Volume | 4,284,806 |
| 52-Week Range | 0.77 - 2.90 |
Best penny stocks to watch in 2021? Here are 3 for your long term watchlist The post Trending Penny Stocks To Watch in 2021?
We're diving back into the world of penny stocks again today as we look at those that are getting the most discussion over on Reddit. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appea...
Investors can seem to get enough of Reddit penny stocks news and we're looking at the most talked-about ones for Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first ...
Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?
CRANFORD, N.J., April 29, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercializat...
Reddit penny stocks are still all the rage from investors that aren't afraid of risks and we're taking a look at the most talked about today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesd...
CRANFORD, N.J., April 22, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercializat...
Reddit penny stocks continue to be a hot topic among investors looking to take out investments in companies without having to break the bank. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thurs...
Reddit penny stocks continue to be a hot subject among retail investors and we're looking at the most-talked-about ones today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared firs...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Executive Chairman Leonard Mazur told Benzinga CEO Jason Raznick Thursday that he's invested $26.5 million of his own money in the specialty pharmaceutical com...
It's a great time to hold CTXR stock as the company's CEO shares his vision of significant corporate developments and clinical progress. The post Capital Raises and Clinical Programs Prove the Progress ...
Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...
Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today ...
CRANFORD, N.J., March 4, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care dru...
CRANFORD, N.J., Feb. 19, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critic...
Citius Pharmaceuticals (CTXR) stock is on the rise Friday with heavy trading of its shares despite a lack of news about the company today. The post CTXR Stock: 9 Things to Know About the Biotech Citius ...
CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., Feb. 16, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care dru...
CRANFORD, N.J., Feb. 2, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug...
CRANFORD, N.J., Jan. 27, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., Dec. 15, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., Dec. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critica...
CRANFORD, N.J., Nov. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., Nov. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug...
Citius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take Off
CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug...
CRANFORD, N.J., Sept. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing criti...
CRANFORD, N.J., Sept. 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing criti...
CRANFORD, N.J., Sept. 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing criti...
CRANFORD, N.J., Sept. 15, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Sept. 8, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., Aug. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., July 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., July 20, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
CRANFORD, N.J., July 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., July 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical c...
Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
CRANFORD, N.J., June 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., June 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., June 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critic...
CRANFORD, N.J., June 2, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critica...
CRANFORD, N.J., May 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critica...
CRANFORD, N.J., May 18, 2020 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today annou...
About CTXR
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast rec... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO Myron Holubiak | Employees 10 |
| Stock Exchange NASDAQ | Ticker Symbol CTXR |
Analyst Forecasts
According to one analyst, the rating for CTXR stock is "Buy" and the 12-month stock price forecast is 6.00.